World Orphan Drug Alliance Expands to China with RareStone Group Partnership
The World Orphan Drug Alliance (WODA) has announced its expansion to China for the first...
Rare / orphan disease drugs
AnnJi Pharma Signs USD 250 Million Licensing Deal with Avenue Therapeutics for Kennedy’s Disease Drug
Taiwan-based AnnJi Pharmaceutical Co., Ltd has announced the signing of a licensing agreement with US...
Novartis’ LNP023 and Janssen’s Tremfya on Track for Breakthrough Designations
The Center for Drug Evaluation (CDE) website indicates that Swiss major Novartis’ (NYSE: NVS) LNP023...
Oricell Therapeutics Closes $45M Series B1 Round for Cellular Immunotherapy
China-based tumor cellular immunotherapeutics developer Oricell Therapeutics Co., Ltd has announced the closing of a...
BRL Medicine Achieves First Cure of Thalassemia Major with BRL-101
Shanghai-based BRL Medicine Inc. has announced a significant breakthrough in the treatment of thalassemia major....
InnoCare Regains Rights to Orelabrutinib as Biogen Terminates Licensing Agreement
Beijing InnoCare Pharma Tech Co., (HKG: 9969), a China-based biotech focusing on cancer and autoimmune...
Kanghong’s KH617 Receives Orphan Drug Designation for Glioblastoma
China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) has announced receiving an Orphan Drug...
Everest Medicines’ Nefecon Included in South Korea’s GIFT Program
China-based Everest Medicines (HKG: 1952) has announced that South Korea’s Ministry of Food and Drug...
Hemay Pharma Completes Series D Financing for Autoimmune and Oncology Drugs
China-based Ganzhou Hemay Pharmaceutical Co., Ltd, an innovative drug developer focused on autoimmune diseases and...
SciClone Pharmaceuticals Files for Hong Kong Market Approval of Danyelza
SciClone Pharmaceuticals Inc. (Nasdaq: SCLN), which became a China-based company after going private in 2017,...
Gracell’s CAR-T Therapy GC012F Receives FDA IND Approval
Shanghai-based biotech Gracell Biotechnologies has reported receiving Investigational New Drug (IND) approval from the US...
Bristol-Myers Squibb’s Ozanimod Approved in China for Multiple Sclerosis
Bristol-Myers Squibb (BMS, NYSE: BMY) has announced receiving marketing approval from China’s National Medical Products...
NeuShen Therapeutics Partners with UMass Chan for ALS Gene Therapy Development
Sino-US biotech firm NeuShen Therapeutics Inc., focused on central nervous system (CNS) disorders, has announced...
Daewoong Pharmaceutical Licenses Bersiporocin to CSP for Greater China Development
South Korea-based Daewoong Pharmaceutical has entered into an exclusive licensing agreement with UK-based CS Pharmaceuticals...
RemeGen’s Telitacicept Gains FDA Approval for Phase III Study in Myasthenia Gravis
China-based RemeGen Co., Ltd (HKG: 9995, SHA: 688331) has announced receiving approval from the US...
HealZen Therapeutics Gains NMPA Approval for HZ-A-018 Clinical Study in Autoimmune Diseases
Hangzhou-based HealZen Therapeutics has announced receiving approval from the National Medical Products Administration (NMPA) to...
InnoCare’s Gunagratinib Shows Promising Data in Cholangiocarcinoma at ASCO-GI 2023
Beijing InnoCare Pharma Tech Co. (HKG: 9969), a China-based biotech specializing in cancer and autoimmune...
CSPC’s Octreotide Long-Acting Injection Approved for Acromegaly Clinical Study
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving approval from the National Medical...
CANbridge Pharmaceuticals Initiates Phase II Dosing for CAN103 in Gaucher Disease
China-based CANbridge Pharmaceuticals, Inc. (HKG: 1228) has announced the first patient dosing in the Phase...
CDE Grants Priority Review to Takeda’s Vonicog Alfa, Zhongmei’s Rilonacept, and Zai Lab’s SUL-DUR
The Center for Drug Evaluation (CDE) has indicated that Takeda’s Vonicog alfa, Zhongmei Huadong Pharma’s...